IP Library › Granted Patent US 7,368,427
Granted Patent B1
US 7,368,427 · App. 09/856,676 · Granted May 6, 2008

GLP-1 analogues

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,368,427
App. No.
09/856,676
Granted
May 6, 2008
Kind
B1
Abstract

The present invention is directed to peptide analogues of glucagon-like peptide-1, the pharmaceutically-acceptable salts thereof, to methods of using such analogues to treat mammals and to pharmaceutical compositions useful therefor comprising said analogues.

Claims (50)

1. A compound wherein said compound is

[D-Ala 8 , Ala 17,22,23,27 , 3-Pal 19,31 , Gaba 34 ]-GLP-1(7-34)NH 2 ;

[D-Ala 8,23,27 , 3-Pal 19,31 ]hGLP-1(7-35)-NH 2 ;

[Ala 18,23,27 , 3-Pal 19,31 ]hGLP-1(7-35)-NH 2 (SEQ ID NO: 83);

[Ala 16,23,27 , 3-Pal 19,31 ]hGLP-1(7-35)-NH 2 (SEQ ID NO: 84);

[Ala 14,23,27 , 3-Pal 19,31 ]hGLP-1(7-35)-NH 2 (SEQ ID NO: 85);

[Ala 22,23,27 , 3-Pal 19,31 ]hGLP-1(7-35)-NH 2 (SEQ ID NO: 86);

[Hppa 7 ]hGLP-1(7-36)-NH 2 (SEQ ID NO: 87);

[Ala 15,23,27 , 3-Pal 19,31 ]hGLP-1(7-35)-NH 2 (SEQ ID NO: 88);

[Ala 17,23,27 , 3-Pal 19,31 ]hGLP-1(7-35)-NH 2 (SEQ ID NO: 89);

[Ala 22,23,27 , 3-Pal 19,31 , Gaba 34 ]hGLP-1(7-34)-NH 2 (SEQ ID NO: 90);

[Ala 15,22,23,27 , 3-Pal 19,31 , Gaba 34 ]hGLP-1(7-34)-NH 2 (SEQ ID NO: 91);

[Ala 17,22,23,27 , 3-Pal 19,31 , Gaba 34 ]hGLP-1(7-34)-NH 2 (SEQ ID NO: 92);

[Ala 18,22,23,27 , 3-Pal 19,31 , Gaba 34 ]hGLP-1(7-34)-NH 2 (SEQ ID NO: 93);

[Ala 21,22,23,27 , 3-Pal 19,31 , Gaba 34 ]hGLP-1(7-34)-NH 2 (SEQ ID NO: 94);

[Ala 22,23,26,27 , 3-Pal 19,31 , Gaba 34 ]hGLP-1(7-34)-NH 2 (SEQ ID NO: 95);

[Ala 22,23,27,32 , 3-Pal 19,31 , Gaba 34 ]hGLP-1(7-34)-NH 2 (SEQ ID NO: 96);

[Ala 22,23,26,27 , 3-Pal 19,31 , Gaba 33 ]hGLP-1(7-33)-NH 2 (SEQ ID NO: 97);

[Ala 22,23,27,31 , 3-Pal 19 , Gaba 33 ]hGLP-1(7-33)-NH 2 (SEQ ID NO: 98);

[Ala 22,23,27,28 , 3-Pal 19,31 , Gaba 33 ]hGLP-1(7-33)-NH 2 (SEQ ID NO: 99);

[Ala 22,23,27,29 , 3-Pal 19,31 , Gaba 33 ]hGLP-1(7-33)-NH 2 (SEQ ID NO: 100);

[Ala 23,27 , 3-Pal 19,31 , Gaba 33 ]hGLP-1(7-33)-NH 2 (SEQ ID NO: 101);

[Ala 20,22,23,27 , 3-Pal 19,31 , Gaba 33 ]hGLP-1(7-33)-NH 2 (SEQ ID NO: 102);

[Ala 22,23,27 , 3-Pal 19,31 , Gaba 33 ]hGLP-1(7-33)-NH 2 (SEQ ID NO: 103);

[Ala 17,22,23,27 , 3-Pal 19,31 , Gaba 33 ]hGLP-1(7-33)-NH 2 (SEQ ID NO: 104);

[D-Ala 10 , Ala 22,23,27 , 3-Pal 19,31 , Gaba 33 ]hGLP-1(7-33)-NH 2 ;

[D-Ala 8 , Ala 17,23,27 , 3-Pal 19,31 ]hGLP-1(7-34)-NH 2 ;

[Ala 17,23,27 , 3-Pal 19,26,31 ]hGLP-1(7-34)-NH 2 (SEQ ID NO: 105);

[D-Ala 8 , Ala 17 , 3-Pal 19,31 ]hGLP-1(7-34)-NH 2 ;

[Ala 17,23,27 , 3-Pal 19,31 ]hGLP-1(7-34)-NH 2 (SEQ ID NO: 106);

[D-Ala 8 , Ala 17,23,27 , 3-Pal 19,31 , Tle 29 ]hGLP-1(7-34)-NH 2 ;

[D-Ala 8 , Ala 17,23,27 , 3-Pal 19,31 , Tle 16 ]hGLP-1(7-34)-NH 2 ;

[D-Ala 8 , Ala 17,23,27 , 3-Pal 19,31 , Gaba 34 ]hGLP-1(7-34)-NH 2 ;

[D-Ala 22 , Ala 17,23,27 , 3-Pal 19,31 , Gaba 34 ]hGLP-1(7-34)-NH 2 ;

[Aib 8 , Ala 17,23,27 , 3-Pal 19,31 , Gaba 34 ]hGLP-1(7-34)-NH 2 (SEQ ID NO: 107);

[D-Ala 8 , Ala 17,22,23,27 , 3-Pal 19,31 ]hGLP-1(7-33)-NH 2 ;

[Aib 8 , Ala 17,22,23,27 , 3-Pal 19,31 ]hGLP-1(7-33)-NH 2 (SEQ ID NO: 108);

[Ala 17,18,23,27 , 3-Pal 19,31 , Gaba 34 ]hGLP-1(7-34)-NH 2 (SEQ ID NO: 109);

[Ala 17,23,27 , 3-Pal 19,31 , Tle 33 , Gaba 34 ]hGLP-1(7-34)-NH 2 (SEQ ID NO: 110);

[Tle 16 , Ala 17,23,27 , 3-Pal 19,31 , Gaba 34 ]hGLP-1(7-34)-NH 2 (SEQ ID NO: 111);

[N-Me-D-Ala 8 , Ala 17,22,23,27 , 3-Pal 19,31 ]hGLP-1(7-33)-NH 2 ;

[Aib 8 , Ala 17,18,22,23,27 , 3-Pal 19,31 ]hGLP-1(7-33)-NH 2 (SEQ ID NO: 112);

[Ala 17,18,22,23,27 , 3-Pal 19,31 , Tle 16,20 , Gaba 34 ]hGLP-1(7-34)-NH 2 (SEQ ID NO: 113);

[D-Ala 8 , Ala 17,18,22,23,27 , 3-Pal 19,31 , Tle 16 , Gaba 34 ]hGLP-1(7-34)-NH 2 ;

[D-Ala 8,22 , Ala 17,18,23,27 , 3-Pal 19,31 , Gaba 34 ]hGLP-1(7-34)-NH 2 ;

[D-Ala 8,18 , Ala 17,22,23,27 , 3-Pal 19,31 , Gaba 34 ]hGLP-1(7-34)-NH 2 ;

[D-Ala 8,17 , Ala 18,22,23,27 , 3-Pal 19,31 , Gaba 34 ]hGLP-1(7-34)-NH 2 ; or

[D-Ala 8 , Ala 17,18,22,23,27 , 3-Pal 19,31 , Gaba 34 ]hGLP-1(7-34)-NH 2 ; or a pharmaceutically acceptable salt thereof.

2. A method of eliciting an agonist effect from a GLP-1 receptor in a subject in need thereof comprising administering to said subject an effective amount of a compound according to claim 1 or a pharmaceutically acceptable salt thereof.

3. A method of treating Type II diabetes, in a subject in need thereof which comprises administering to said subject an effective amount of a compound according to claim 1 or a pharmaceutically acceptable salt thereof.

Assignments (4)
CHANGE OF NAME Recorded Feb 11, 2009
From: SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES, S.A.S.
To: IPSEN PHARMA S.A.S.
Reel/Frame 022240/0332 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 24, 2001
From: BIOMEASURE, INCORPORATED
To: SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES, S.A.S.
Reel/Frame 011891/0743 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 25, 2001
From: COY, DAVID H.
To: ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND, THE
Reel/Frame 011782/0130 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 18, 2001
From: DONG, ZHENG XIN
To: BIOMEASURE, INCORPORATED
Reel/Frame 011990/0732 →